Author(s):
Bijesh Vatakkeel, Mythreyi R, Siju EN
Email(s):
mythreyir@care.edu.in
DOI:
10.52711/0974-360X.2024.00925 
Address:
Bijesh Vatakkeel1, Mythreyi R1*, Siju EN2
1Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam, 603103, Tamilnadu, India.
2Department of Pharmacology, College of Pharmaceutical Science, Government Medical College, Kannur, Kerala.
*Corresponding Author
Published In:
Volume - 17,
Issue - 12,
Year - 2024
ABSTRACT:
Alzheimer's is a progressive loss of cognitive ability due to neuronal cell degeneration in the brain. It accounts for most dementia cases globally. The multi-factorial etiology of Alzheimer's disease makes currently approved medications like anticholinesterase and glutamate antagonists, inadequate for prevention or cure. They offer only symptomatic relief and do not reverse the neurodegenerative pathways in Alzheimer's disease. Thus, researchers focus on understanding different facets of pathogenesis targeting multiple mechanisms to develop a successful anti-Alzheimer medication. This review discusses Different screening models in various species, developed by scientists, from conventional to transgenic models. Behavioral studies assess the cognition-enhancing potential of new medications under development in Alzheimer's disease models. In this review, we also focussed on the mechanism of pathogenesis in different models which will be helpful in assessing therapeutic activity in different forms of Alzheimer's disease
Cite this article:
Bijesh Vatakkeel, Mythreyi R, Siju EN. Experimental models and behavioral screening tests in Alzheimer's Drug development: A Review. Research Journal Pharmacy and Technology. 2024;17(12):6102-6. doi: 10.52711/0974-360X.2024.00925
Cite(Electronic):
Bijesh Vatakkeel, Mythreyi R, Siju EN. Experimental models and behavioral screening tests in Alzheimer's Drug development: A Review. Research Journal Pharmacy and Technology. 2024;17(12):6102-6. doi: 10.52711/0974-360X.2024.00925 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-12-62
REFERENCE:
1. Shatabdi Choudhury, Chitra Vellapandian. Alzheimer’s Disease Pathophysiology and its Implications. Research J. Pharm. and Tech. 2019; 12(4): 2045-2048. doi: 10.5958/0974-360X.2019.00338.
2. Calabro M, Rinaldi C et al. The biological pathways of Alzheimer's disease: a review. AIMS Neurosci. 2020; 16; 8(1): 86-132. Doi: 10.3934/Neuroscience.2021005.
3. Roda A et al. Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural Regen Res. 2022; 17: 1666–1674. Doi: 10.4103/1673-5374.332127.
4. Konig T, Stogmann E. Genetics of Alzheimer's disease. Wien Med Wochenschr. 2021; 171(11-12): 249-256. Doi: 10.1007/s10354-021-00819-9. Epub 2021 Feb 22.
5. Athar T et al. Recent advances in drug development and emerging therapeutic agents for Alzheimer’s disease. Mol. Biol. Rep. 2021; 48: 5629–5645. https://doi.org/10.1007/s11033-021-06512-9
6. Husain A et al. Coumarin linked heterocyclic hybrids: a promising approach to develop multi-target drugs for Alzheimer’s disease. J. Mol. Struct. 2021; 241:130618
7. Neha et al. Animal models of dementia and cognitive dysfunction. Life Sci. 2014; 109(2): 73−86.
8. Chen ZY, Zhang Y. Animal models of Alzheimer's disease: Applications, evaluation, and perspectives. Zool Res. 2022; 18; 43(6): 1026-1040. Doi: 10.24272/j.issn.2095-8137.2022.289.
9. Li Y, Gu BJ. Non-human Primate Models of Alzheimer’s Disease. J. Explor. Res. Pharmacol. 2023.
11. Hsiao K et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 4; 274(5284): 99-102
12. Ahlijanian MK et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(6): 2910–2915. doi: 10.1073/pnas.040577797.
13. Games D et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature. 1995; 373(6514): 523-7.
14. Hsiao K et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996; 4; 274(5284): 99-102.
15. Sturchler PC et al. Two amyloid precursor protein transgenic mouse models with Alzheimer's disease-like pathology. Proc Natl Acad Sci U S A. 1997; 94(24): 13287-92.
16. Mucke L et al. High-level neuronal expression of a beta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000; 1; 20(11): 4050-8.
17. Radde R et al. A beta 42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006; 7(9): 940-6.
18. Mann KM et al. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet. 2004; 1; 13(17): 1959-68.
19. Oddo S et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003; 39(3): 409-21.
20. Billings LM et al. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005; 45(5): 675-88
21. Sadleir KR et al. ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease. J Biol Chem. 2018; 293(48): 18434-18443.
22. Leon WC et al. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010; 20(1):113-26.
23. Sun XQ et al. miR-342-5p decreases ankyrin G levels in Alzheimer's disease transgenic mouse models. Cell Report. 2014; 6(2): 264–270. doi: 10.1016/j.celrep.2013.12.028.
24. Cohen RM et al. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci. 2013; 33(15): 6245-56.
25. Yamada K et al. A beta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. 2009; J Neurosci. 29(36): 11393
26. Audrain M et al. βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease. Cereb Cortex. 2017; 18: 1-18.
27. Vidal R et al. A decamer duplication in the 3' region of the BRI gene originates an amyloid peptide that is associated with dementia in Danish kindred. Proc Natl Acad Sci U S A. 2000; 25; 97(9): 4920-5
28. Neuner SM et al. Genetic Complexity to Enhance Translatability of Alzheimer's Disease Mouse Models: A Path toward Precision Medicine. Neuron. 2019; 101(3): 399-411.
29. Prashant Bharadwaj et al.Yeast as a model for studying Alzheimer's disease, FEMS Yeast Research 2010; 10(8): 961–969.
30. Brandt R et al. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer’s disease-like modified tau. Neurobiol. Aging. 2009; 30: 22–33. doi: 10.1016/j.neurobiolaging.2007.05.011
31. Prubing K et al. Drosophila melanogaster as a model organism for Alzheimer's disease. Mol Neurodegener. 2013; 22: 8:35. doi 10.1186/1750-1326-8-35. PMID: 24267573; PMCID: PMC4222597.
32. Sandra C et al. Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery, Biomedicine & Pharmacotherapy. 2022; 149: 112924. ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2022.112924
33. Barnes, C. A. Memory deficits associated with senescence: A neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979; 93 (1): 74–104
34. Nakai T et al. Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. Int J Mol Sci. 2021: May 24; 22(11): 5549. doi: 10.3390/ijms22115549.
35. Fendt M, Fanselow MS. The neuroanatomical and neurochemical basis of conditioned fear. 1999 Neurosci Bio Behav Reviews. 1999. 23:743-760.
36. Arts JW et al. Working and reference memory of pigs in the spatial hole board discrimination task. Behavioural Brain Research. 2009; 205(1); 303–306. doi 10.1016/j.bbr.2009.06.014.
37. Saifullah et al. Touchscreen-based location discrimination and paired associate learning tasks detect cognitive impairment at an early stage in an App knock-in mouse model of Alzheimer's disease. Mol Brain. 2020; 13; 13(1): 147. doi 10.1186/s13041-020-00690-6.
38. Bromley-Brits K et al.Morris water maze test for learning and memory deficits in Alzheimer's disease model mice. J Vis Exp. 2011; 20; (53): 2920. doi 10.3791/2920.
39. Bengoetxea X et al.Object recognition test for studying cognitive impairments in animal models of Alzheimer's disease. Front Biosci (Schol Ed). 2015; 7(1): 10-29. doi 10.2741/S421.
40. Alamed J et al.Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc. 2006; 1(4): 1671-9. doi 10.1038/nprot.2006.275. PMID: 17487150
41. Whyte LS et al. Reduction in open field activity in the absence of memory deficits in the AppNL-G-F knock-in mouse model of Alzheimer's disease. Behav Brain Res. 2018; 15; 336: 177-181. doi 10.1016/j.bbr.2017.09.006. Epub 2017 Sep 5.
42. Bryan KJ et al. Transgenic Mouse Models of Alzheimer’s Disease: Behavioral Testing and Considerations. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis. 2009; Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK5231.
43. Kraeuter AK et al. The Y-Maze for Assessment of Spatial Working and Reference Memory in Mice. Methods Mol Biol. 2019; 1916: 105-111. doi 10.1007/978-1-4939-8994-2_10.
44. Komada M et al. Elevated plus maze for mice. J. Vis. Exp. 2008; 22, (22): 1088. Doi: 10.3791/1088. PMID: 19229173.
45. Dipsundar Sahu et al., Potential Ayurvedic Herbs for Neurodegenerative Diseases: A review, Research Journal of Pharmacology and Pharmacodynamics, 2021, vol.15, 213-227.
46. Anjaneyulu Konuri et al.,Dietary Supplementation of Fenugreek Seed Extract and Choline- Docosahexaenoic acid on Oxidative Stress and Neurodegeneration in Ovariectomized Rats with Bilateral Common Carotid Artery Occlusion, Research Journal of Pharmacy and Technology. 2021; 10: 381.
47. Hemalatha Bangera et al.,Assessment of behavioral and anatomical changes in anterior Cingulate gyrus and Substantia nigra in stressed adult albino mice, Research Journal of Pharmacy and Technology, 2022; 10: 886
48. Rachagolla Sai Prathap Yadav et al.,In vivo Acetylcholinesterase activity and Antioxidant property of Cucurbita pepo ethanolic extract in Alzheimer’s disease induced by Aluminium chloride in Sprague Dawley rat model, Research Journal of Pharmacy and Technology, 2023; 10: 178.
49. M.Vijey Aanandhi et.al., A Comprehensive Review on the Role of Tau Proteins in Alzheimer’s Pathology, Research Journal of Pharmacy and Technology, 2018; 10: 149.
50. Shatabdi Choudhury et.al.,Alzheimer’s Disease Pathophysiology and its Implications, Research Journal of Pharmacy and Technology. 2019; 10: 338.
51. Tamilselvan. M et.al., Unfolding Remedial Targets for Alzheimer’s Disease, Research Journal of Pharmacy and Technology. 2020; 534.
52. Anjaneyulu Konuri et al.,Dietary Supplementation of Fenugreek Seed Extract and Choline-Docosahexaenoic acid on Oxidative Stress and Neurodegeneration in Ovariectomized Rats with Bilateral Common Carotid Artery Occlusion, Research J. Pharm. and Tech. 2021; 14(4): 2153.